BIOA

BioAge Labs, Inc.

Insider Trades

NameValueActionPriceCurrent Price
Rubin Paul DChief Medical Officer
$157k8.8k shares
SellApr 1, 2026
$17.81
--
Rubin Paul DChief Medical Officer
$151k7.4k shares
SellMar 2, 2026
$20.30
--
Rubin Paul DChief Medical Officer
$139k7.4k shares
SellFeb 2, 2026
$18.75
--
Fortney KristenDirector, Officer: Chief Executive Officer
$4.2M233.1k shares
SellJan 13, 2026
$18.12
--
Goldstein Dov A MDChief Financial Officer
$240k11.7k shares
SellJan 13, 2026
$20.54
--
Goldstein Dov A MDChief Financial Officer
$165k9k shares
SellJan 13, 2026
$18.43
--

News

globenewswire.comBioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Riskglobenewswire.comJun 16globenewswire.comBioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Riskglobenewswire.comJun 16seekingalpha.comBioAge Labs, Inc. (BIOA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.comJun 8marketbeat.comBioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Diseasemarketbeat.comJun 6globenewswire.comBioAge Labs to Present at Upcoming Investor Conferencesglobenewswire.comMay 22